Literature DB >> 14563453

Plasma lipid and lipoprotein concentrations in pregnancy induced hypertension.

Mustafa Baki Cekmen1, Ayse Binnur Erbagci, Ayse Balat, Can Duman, Hale Maral, Kivanc Ergen, Meltem Ozden, Ozcan Balat, Sevinc Kuskay.   

Abstract

OBJECTIVES: Aim of this study was to evaluate implication of pregnancy induced hypertension on maternal plasma lipid, lipoprotein, apolipoprotein concentrations and lipid peroxidation products by a comparison of normal pregnancy vs. preeclampsia. DESIGN AND METHODS: Thirty-four women with preeclampsia and 32 healthy pregnant women (controls) in the third trimester were recruited for this study.
RESULTS: In the preeclamptic group plasma total triglyceride, low density lipoprotein cholesterol (LDL-C), malondialdehyde (MDA) and apolipoprotein B (apo-B) were significantly increased, while plasma high density lipoprotein cholesterol (HDL-C) was significantly decreased compared to that of control group. There was no significant difference in total cholesterol and apolipoprotein A1 (apo-A1) concentrations.
CONCLUSION: Our findings suggest that preeclampsia share some metabolic characteristics with coronary artery disease such as dislipidemia and increased lipid peroxidation. However lipoprotein concentrations may be better biochemical markers of dislipidemia in the preeclamptic state than the corresponding apolipoproteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563453     DOI: 10.1016/s0009-9120(03)00099-7

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  17 in total

1.  Study of serum lipid profile in pregnancy induced hypertension.

Authors:  Jayanta De; Ananda Mukhopadhyay; Pradip Kumar Saha
Journal:  Indian J Clin Biochem       Date:  2006-09

2.  A Study on Atherogenic Indices of Pregnancy Induced Hypertension Patients as Compared to Normal Pregnant Women.

Authors:  Meenakshi Singh; Mauchumi Saikia Pathak; Anindita Paul
Journal:  J Clin Diagn Res       Date:  2015-07-01

3.  Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis.

Authors:  Cassandra N Spracklen; Caitlin J Smith; Audrey F Saftlas; Jennifer G Robinson; Kelli K Ryckman
Journal:  Am J Epidemiol       Date:  2014-07-02       Impact factor: 4.897

4.  Serum βhCG and Lipid Profile in Early Second Trimester as Predictors of Pregnancy-Induced Hypertension.

Authors:  Kiran Yadav; Shalini Aggarwal; Kamlesh Verma
Journal:  J Obstet Gynaecol India       Date:  2013-12-17

5.  Association of Lipid Profile and Uric Acid with Pre-eclampsia of Third Trimester in Nullipara Women.

Authors:  Vibhuti Agarwal; Bharat Kumar Gupta; Abhishek Vishnu; Jas Kiran
Journal:  J Clin Diagn Res       Date:  2014-07-20

Review 6.  Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms.

Authors:  Frank T Spradley; Ana C Palei; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-07       Impact factor: 3.619

7.  Serum lecithin: cholesterol acyltransferase activity, HDL2 and HDL3 composition in hypertensive mothers and their small for gestational age newborns.

Authors:  B Loukidi-Bouchenak; M Y Lamri-Senhadji; S Merzouk; H Merzouk; B Belarbi; J Prost; J Belleville; M Bouchenak
Journal:  Eur J Pediatr       Date:  2007-06-29       Impact factor: 3.183

8.  Differential proteome analysis of the preeclamptic placenta using optimized protein extraction.

Authors:  Magnus Centlow; Stefan R Hansson; Charlotte Welinder
Journal:  J Biomed Biotechnol       Date:  2009-09-13

9.  Serum Cholesterol and Ceruloplasmin Levels in Second Trimester can Predict Development of Pre-eclampsia.

Authors:  Madhusudan Dey; Devendra Arora; Nagarja Narayan; Reema Kumar
Journal:  N Am J Med Sci       Date:  2013-01

10.  Risk factors for preeclampsia in women from Colombia: a case-control study.

Authors:  Laura M Reyes; Ronald G García; Silvia L Ruiz; Paul A Camacho; Maria B Ospina; Gustavo Aroca; Jose L Accini; Patricio López-Jaramillo
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.